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A B S T R A C T
In dry powder inhalers (DPIs) the patient’s inhalation manoeuvre strongly inﬂuences the release of drug.
Drug release from a DPI may also be inﬂuenced by the size of any air bypass incorporated in the device. If
the amount of bypass is high less air ﬂows through the entrainment geometry and the release rate is
lower. In this study we propose to reduce the intra- and inter-patient variations of drug release by
controlling the amount of air bypass in a DPI. A fast computational method is proposed that can predict
how much bypass is needed for a speciﬁed drug delivery rate for a particular patient. This method uses a
meta-model which was constructed using multiphase computational ﬂuid dynamic (CFD) simulations.
The meta-model is applied in an optimization framework to predict the required amount of bypass
needed for drug delivery that is similar to a desired target release behaviour. The meta-model was
successfully validated by comparing its predictions to results from additional CFD simulations. The
optimization framework has been applied to identify the optimal amount of bypass needed for ﬁctitious
sample inhalation manoeuvres in order to deliver a target powder release proﬁle for two patients.
© 2017 Elsevier B.V. All rights reserved.
Contents lists available at ScienceDirect
International Journal of Pharmaceutics
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Dry powder inhalers (DPI) are devices used to deliver drug
powder to the pulmonary airways of a patient. In DPIs drug powder
is initially stored in an entrainment compartment. Typically, this is
a pre-ﬁlled and foil sealed ‘blister’ that is pierced or opened to
allow air to ﬂow through. When a patient inhales through the
device, the ﬂow of air entrains the powder and delivers it to the
lung. Since the patient generates the inhalation airﬂow him/
herself, drug delivery by means of a DPI is inherently variable and
highly patient dependent: when a patient generates a strong
inhalation ﬂow rate drug is entrained comparably faster. However,
for optimal delivery it is desired to design DPIs that can deliver
drug to similar pulmonary airways, independent of a patient’s
ability to use a device. There have been various attempts to
improve DPI drug delivery by studying and optimizing different
parts of a DPI. For example, these attempts include: (i) numerical
optimization of the entrainment compartment of a DPI (KopschAbbreviations: CFD, computational ﬂuid dynamics; DPI, dry powder inhaler; EE,
Eulerian-Eulerian; MDI, metered dose inhaler.
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0378-5173/© 2017 Elsevier B.V. All rights reserved.et al., 2016a; Zimarev et al., 2013), (ii) experimental investigation of
the effect of add-on spacers on de-agglomeration (Ehtezazi et al.,
2008) and (iii) numerical investigations into the effect of DPI
geometry on powder de-agglomeration (Chen et al., 2013; Coates
et al., 2006; Wong et al., 2011a,b, 2010).
Controlling de-agglomeration of drug particles during the
entrainment process is necessary to deliver the formulation to the
correct pulmonary regions: small particles (d < 5 mm) are typically
cohesive and thus form large agglomerates (d > 10 mm). Such
agglomerates are not easily inhalable due to their aerodynamic
properties. Good lung deposition requires particle sizes between
0.1 mm and 10 mm (Heyder, 2004). It is therefore a key requirement
for effective drug delivery that agglomerates of particles are
broken up in the device during inhalation. Wong et al. evaluated
the inﬂuence of turbulence (Wong et al., 2010) and impaction
(Wong et al., 2011a,b) on de-agglomeration; impaction was found
to be most effective.
There is an opportunity to apply numerical techniques, such as
computational ﬂuid dynamics (CFD), to the development of DPIs.
Multiphase CFD techniques have been successfully applied to
predict the entrainment of drug in a DPI (Milenkovic et al., 2014;
Tong et al., 2013; Wong et al., 2011b). Consequently, in our previous
work, we applied a CFD technique to optimize the entrainment
geometry of a DPI (Kopsch et al., 2016a; 2015; Zimarev et al., 2013).
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(A) is independent of the inhalation manoeuvre and (B) targets the
dose to a speciﬁc pulmonary region in the lung. This optimization
objective was achieved by using a multiphase CFD technique to
predict the rate of drug release from an entrainment geometry for
two different sample inhalation proﬁles. The predicted rate of drug
entrainment was used to calculate the value of a cost function that
quantiﬁed the optimization objectives (A) and (B). Finally, the
entrainment geometry was systematically varied to achieve lower
values of the cost function. The result was an optimized DPI
entrainment geometry that achieved better performance in terms
of the objectives (A) and (B).
Even though some theoretical progress has been made to
reduce patient dependence of DPI drug dose delivery, no practical
solution is currently on the market. Drug delivery by means of a DPI
is still considered less reliable than delivery by other types of
inhalers, i.e. nebulizers or metered dose inhalers (MDIs). One
reason is that devices are often made to be used by a wide range of
patients (a ‘one size ﬁts all’ approach). In this study, we investigate,
by computational method, if a DPI design can be personalized for
the patients it is intended to treat. We propose the amount of air
bypass as a DPI design factor to control powder entrainment rate
when the entrainment geometry design has been ‘locked down’
and present a fast computational method that can determine the
optimal amount of bypass needed to minimize the variability in
drug delivery rate between different inhalation manoeuvres of a
given patient. The computational method uses measurements of
several inhalation proﬁles of a particular patient to predict the
effect of varying the amount of air bypass in a DPI for that patient.
We validate the computational method and demonstrate by means
of numerical simulations how such a method may be used to
achieve the optimization objective, i.e. to target the dose to a
speciﬁc pulmonary region in the lung. The focus of this work is to
develop the computational method, not the design of a new DPI per
se, since inhaled products are often retro-engineered into existing
commercial platform devices. Therefore, the current approach
adopts an existing DPI design where other design elements have
been locked down (for example, in the generic design shown in
Fig. 1), to study the effect of varying of the magnitude of airﬂow
through the bypass channel.
2. Methods
2.1. Concept development
A simple DPI layout may be thought of as an entrainment
compartment and a bypass element in parallel, see Fig. 2. When
patients inhale through the device, they generate a total ﬂow rate
Q tð Þ. The incoming air divides so that a portion of the air ﬂows
through the entrainment compartment, where it may entrain drug
powder, and the remainder ﬂows through the bypass element. TheFig. 1. Simpliﬁed drawing of a DPI (top removed) with a blister (powder entrainment com
amount of air that bypasses the blister.ﬂow rates through the entrainment compartment and the bypass
element are Qent tð Þ and Qbypass tð Þ respectively.
Note that the inhaled volume of air V tð Þ is the integral of the
total ﬂow rate Q tð Þ over time.
V tð Þ ¼
Z t
0
Q t0ð Þdt0 ð1Þ
However, M tð Þ, the mass of drug powder released as a function
of time t, only depends on the ﬂow rate through the entrainment
compartment Qent tð Þ. In pharmaceutical applications it is impor-
tant when the drug is released with respect to the total volume of
inhaled air Vtot, because this determines which pulmonary
locations the drug may be able to reach. Drug released early in
the tidal inhalation ﬂow can penetrate deeply into the expanding
lungs, whereas later released drug will only reach the upper
airways. As explained in Kopsch et al. (2016a, 2015), it is
convenient to express the mass of released drug M as a fraction
x of the scaled volume, where
x ¼ V tð Þ
Vtot
ð2Þ
The relative ﬂow resistances of the entrainment compartment
and the bypass element control the amount of air that ﬂows
through each part. For example, if the ﬂow resistance of the bypass
element is increased then more air will ﬂow through the
entrainment compartment. DPIs may be characterized by the
bypass ratio
r ¼ Qbypass
Qent
ð3Þ
Ifeffectsdue tothepresenceof thedrug powderareneglectedthis
ratio is approximately constant during an inhalation manoeuvre. For
most commercially available DPIs the bypass ratio is ﬁxed at
manufacture. However, it may be beneﬁcial to adapt this ratio to the
patient. A patient who generates a lower total inhalation ﬂow rate
may choose a lower ratio r in order to still achieve a good ﬂow rate
Qent through the entrainment compartment.
As an illustration, Fig. 3 shows the inﬂuence of r on the timing of
drug release: Fig. 3a shows three possible measurements of
inhalation ﬂow rate Q tð Þ through a DPI. Correspondingly, Fig. 3b–d
shows the released drug as a function of scaled volume x for low,
medium and high amounts of bypass respectively. As indicated a
low bypass can achieve an early delivery of drug, while a high
bypass achieves a more continuous delivery. The amount of bypass
may be ‘tuned’ to achieve a better match with a desired release
proﬁle.
2.2. Development of a meta-model
The goal is to predict M xð Þ, the mass of drug that has left the
entrainment part as a function of scaled volume x, for any givenpartment) and a ﬁxed bypass. The dimensions of the bypass channel inﬂuence the
Fig. 2. Schematic layout of a DPI showing a bypass channel (with deﬁnable ﬂow resistance) in parallel with an entrainment compartment with deﬁned ﬂow resistance.
Fig. 3. Idealized representation of inhalation ﬂow rate released drug as a function of scaled volume for different bypasses. Example data for clariﬁcation purposes only. (a)
Three simulations of inhalation ﬂow rates. Corresponding drug release proﬁles for: (b) low bypass, (c) medium bypass, and (d) high bypass.
T. Kopsch et al. / International Journal of Pharmaceutics 529 (2017) 589–596 591inhalation ﬂow rate proﬁle Q tð Þ. M xð Þ may be predicted using
multiphase CFD simulations. However, high-ﬁdelity CFD simu-
lations tend to be computationally expensive and may not be
practical in cases where a large number of predictions are required.
For this reason a meta-model was constructed. A meta-model is a
simpliﬁed model of a complex calculation. A (small) number of
computationally expensive simulation results are used to build a
lower ﬁdelity model that can predict further results with low
computational cost. Here, the meta-model was constructed in the
following way. First, a number of high-ﬁdelity (computationally-
expensive), two phase CFD simulations of a particular entrainment
compartment were conducted to predict M tð Þ, the mass of released
drug as a function of time t, for a range of different ﬂow rate proﬁlesFig. 4. The entrainment geometry used in this study (dimensions in mm). This is one of th
represents the initial distribution of drug powder.Qent tð Þ. Second, using the CFD results a meta-model was
constructed by interpolating between data points. This meta-
model can be used to predict M tð Þ for further new ﬂow rate proﬁles
for the chosen entrainment geometry.
2.2.1. Computational ﬂuid dynamics approach
A two phase Eulerian–Eulerian (EE) CFD approach was applied
to simulate the entrainment of drug powder in the entrainment
compartment of a DPI. ANSYS Fluent (ANSYS, 2009) was used to
model the transient entrainment of drug formulation when
different constant ﬂow rates Qent were applied at the outlet of
the device. The 2D entrainment geometry chosen in this work is
shown in Fig. 4. This entrainment geometry is one of threee optimized geometries found by Kopsch et al. (2016a). The area shaded in dark grey
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2016a). It achieved low costs in terms of objective A, i.e. low
patient-to-patient variability. Furthermore, it also achieved low
costs in terms of objective B: to deliver an early bolus of drug.
ANSYS Meshing was used to mesh the geometry. The target cell
size was 0.05 mm, which resulted in 8076 cells. The CFD solver
settings for ANSYS Fluent that were used in this study are
presented in Table 1. In previous studies (Kopsch et al., 2016a,b) it
has been shown that these settings can produce results that are in
good agreement with experimental results from Tuley et al. (2008)
and are comparable to results achieved with a different CFD solver
(OpenFOAM (The OpenFOAM Foundation, 2016)).
The outlet boundary conditions were transient inhalation ﬂow
rate proﬁles. When a ﬂow rate proﬁle Qent is applied at the outlet,
the entrainment of drug powder in the compartment can be
monitored as a function of time t. From the simulation the mass of
drug released from the device, M tð Þ, was calculated as a function of
time.
2.2.2. Predicting the entrainment behaviour with the meta-model
The aim was to use a ﬁnite number of CFD simulations to
construct a simpliﬁed meta-model that is able to predict M tð Þ for
different Qent tð Þ. Once the meta-model is constructed, it may be
used to predict M tð Þ for different Qent tð Þ without running further
CFD simulations. Since the meta-model is only a simpliﬁed
description of complex CFD entrainment simulations, it is not
able to capture details of the ﬂuid ﬂow.
In this meta-model it is assumed that dMdt , the rate of mass
entrainment, may be modelled as a function of only two variables,
the instantaneously applied ﬂow rate Qent and the amount of drug
remaining in the device (or, equivalently, the amount released
from the device M). Thus
dM
dt
¼ F M; Qentð Þ ð4Þ
In fact the exact mass ﬂow rate of powder exiting the device at a
particular time will depend on the exact distribution (i.e. volume
fraction) and ﬂow velocities of powder and air over the whole
modelled domain at that particular instant. However, provided
that Qent does not vary very rapidly compared to the transit time
for ﬂow through the domain and that the ﬂow regime does not
signiﬁcantly change (as characterised by the Reynolds and Stokes
numbers), the approximation of Eq. (4) is expected to be
satisfactory for our purposes.
In order to estimate an approximate functional relationship
F M; Qentð Þ the results of 20 CFD simulations have been used. In each
of these CFD simulations a different constant ﬂow rate Qent has
been applied at the outlet, yielding different M tð Þ. As an
illustration, Fig. 5a shows how two different constant inhalation
ﬂowrates Qent result in different release proﬁles M tð Þ. Fig. 5b
shows the rate of drug release dMdt as a function of time.
dM
dt may also
be expressed as a function of M, see Fig. 5c. The area shaded in greyTable 1
CFD solver settings for EE ANSYS Fluent (ANSYS, 2009) simulation.
CFD Modeling Parameter 
Inlet boundary condition 
Outlet boundary condition 
Granular viscosity model 
Frictional viscosity model 
Granular temperature 
Solids pressure 
Radial distribution 
Drag coefﬁcient is the region in which values for the model F M; Qentð Þ can be
interpolated from the results of these two CFD simulations.
In this study F has been approximated from the CFD results
using a Python (Python Software Foundation, 2016) script. Bilinear
interpolation was applied to predict values for dMdt for points
M; Qentð Þ that lie between two curves. Bilinear interpolation was
chosen because of its simplicity compared to other predictive
modelling approaches. Once the numerical approximation for F is
known Eq. (4), a differential equation, may be solved numerically
to predict M tð Þ for any speciﬁed ﬂow rate proﬁle Qent tð Þ. The
Python library SciPy (The Scipy community, 2016) has been used to
solve this equation numerically.
2.3. Optimization of the bypass ratio
Given a set of N measurements of inhalation proﬁles, the ratio of
bypass to main entrainment ﬂow r (see Eq. (3)) that best achieves a
desired drug release behaviour is sought. This is an optimization
problem. By systematically varying the parameter r it is hoped to
minimize a cost function C that represents the degree to which
desired drug release behaviour is achieved.
2.3.1. Optimization objective
For each inhalation ﬂow rate measurement Qi tð Þ the meta-
model described in Section 2.2 can predict the corresponding drug
release proﬁle Mi xð Þ. For many therapeutic applications it is
desired to achieve an early bolus delivery of drug. Such a target
release proﬁle may be deﬁned as
Mtarget xð Þ ¼ Mtot
x
x0
if x < x0
Mtot if x  x0
( )
ð5Þ
This is a ‘ramp’ function that reaches total release of drug Mtot
after a fraction x0 of inhaled air volume. The optimization goal is to
achieve drug release proﬁles Mi xð Þ as close as possible to the target
proﬁle Mtarget xð Þ. We choose to measure the difference between
Mi xð Þ and Mtarget xð Þ with the integral
Ci ¼
Z 1
0
Mi xð Þ  Mtarget
 2dx ð6Þ
The total cost function is the average of all Ci for the N measured
breath proﬁles:
C ¼ 1
N
XN
i¼1 Ci ð7Þ
The approach to calculate the cost function C is illustrated in
Fig. 6. Fig. 6a shows N = 3 inhalation ﬂow rate proﬁles Qi tð Þ (i = 1, 2,
3). Accordingly, Fig. 6b shows the resulting drug release proﬁles
Mi xð Þ and the target function Mtarget xð Þ. As an example, the area of
the graph shaded grey shows the difference between Proﬁle 1 and
the target; this difference determines the value of the cost function
C1.Value or Model
Atmospheric pressure (101,325 Pa)
A transient ﬂow rate proﬁle Qent tð Þ
‘Gidaspow’ (Gidaspow et al. (1992))
‘Johnson et al.’ (Johnson and Jackson (1987))
‘Algebraic’
‘Lun et al.’ (Ding and Gidaspow (1990), Lun et al. (1984))
‘Lun et al.’ (Ding and Gidaspow (1990), Lun et al. (1984))
‘Gidaspow’ (Gidaspow et al. (1992))
Fig. 5. Idealized representations of drug release M and the rate of drug release dMdt as functions of time t and of each other. Example data for clariﬁcation purposes only.
(a) Two drug release proﬁles M as a function of time t for two different entrainment ﬂow rates Qent. (b) The corresponding proﬁles of rate of drug release dMdt as
a function of time t. (c) dMdt as a function of M for the same two proﬁles. The area between the two graphs is indicated in grey.
Fig. 6. Idealized representations of the process to calculate the cost function. Example data for clariﬁcation purposes only. (a) N = 3 inhalation ﬂowrate proﬁles Qi tð Þ. (b) The
resulting mass release proﬁles Mi xð Þ and the target release proﬁle Mtarget xð Þ for x0 ¼ 13. The difference between M1 and the target proﬁle is shaded grey and
determines the cost C1.
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Fig. 7 shows the method used to obtain the optimal ratio r of
bypass to main entrainment ﬂow. First, measurements of N
different inhalation proﬁles Qi tð Þ of a speciﬁc patient are needed.
Given a particular choice of the ratio r, and by applying the meta-
model presented in Section 2.2, the drug release proﬁles Mi xð Þ are
then predicted for all inhalation proﬁles. Consequently, the cost
function C (Eq. (7)) may be calculated. Next r is varied
systematically, using a steepest gradient descent algorithm
(Nocedal and Wright, 2006), to minimize C. When no further
reductions of C can be achieved the result is considered to have
converged and the corresponding value of r to be optimal.
3. Results
3.1. Validation of the meta-model approach
The EE CFD method used in this study has been partially
validated in our previous work (Kopsch et al., 2016a; Zimarev et al.,
2013). This was accomplished by comparing CFD results to
experimental data, i.e. from Tuley et al. (2008), and to resultsfrom another CFD solver: OpenFOAM (The OpenFOAM Foundation,
2016). For this reason, it was assumed that the chosen EE approach
is able to generate realistic results. In order to construct the meta-
model 20 EE CFD simulations with different constant inhalation
ﬂow rates Qent have been conducted for the entrainment geometry
shown in Fig. 4. After the meta-model was constructed, its
performance was tested using independent CFD results. Testing is
important to ensure that (i) the complexity of the chosen model
and (ii) the number of CFD simulations used to construct the model
are sufﬁcient to make reasonable predictions.
The goal of the meta-model was to express dMdt as a function of M
and Qent, as described in Section 2.2. Fig. 8a shows the rate of drug
entrainment dMdt as a function of drug released from the device M for
ﬁve different (constant) ﬂow rates. As shown in Fig. 8a the rate of
entrainment dMdt tends to zero when the ﬂow rate Qent is small and
when most of the drug is released (i.e. when M approaches Mtot).
This is expected, because drug cannot be entrained either at small
ﬂow rates or when no drug is left in the DPI compartment. The
peaks observed in the dMdt  M plots represent occasions when a
bolus of drug is released.
Fig. 7. The optimization framework uses N measurements of inhalation proﬁle to predict the required amount of bypass.
Fig. 8. (a) The rate of drug entrainment dMdt as a function of ﬂow rate Qent and released mass of drug M. (b) Drug release as a function of time for three different
inhalation proﬁles. The solid lines show CFD results, the dotted lines correspond to predictions made by the meta model.
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the drug released M tð Þ. The meta-model has been tested by
predicting M tð Þ proﬁles for new ﬂow rate proﬁles Qent tð Þ that were
not previously used to construct the meta-model. These pre-
dictions were then compared to predictions made using new CFD
simulations, see Fig. 8b. Fig. 8b shows reasonable agreement
between the meta-model and new CFD simulations for the three
cases tested. The agreement is especially good for proﬁles 1 and 3.
If higher accuracy is needed, the meta-model may be reﬁned
further. This could be achieved by using more CFD simulations to
construct the meta-model. The key advantage of the meta-model
compared to CFD simulations is the saving of computation costs.
While a typical CFD simulation takes around three hours to
complete on a standard desktop personal computer, the meta-
model can make a prediction within milliseconds.In summary, the meta-model presented gives reasonable
agreement with additional CFD simulations. Therefore it is
considered appropriate to predict the release of drug in a DPI
for different inhalation ﬂow rate proﬁles.
3.2. Application of the bypass optimization approach
As an example, the optimization framework has been applied to
calculate the optimal ratio r for two ﬁctitious patients. Patient 1
can reach peak inspiratory ﬂow rates between 60 and 80 L min1,
see Fig. 9a. These ﬂow rates are representative for healthy subjects
or asthmatic patients with good lung function (de Koning et al.,
2002; Persson et al., 1997; Tarsin et al., 2006). Patient 2 has poorer
lung function, and can only achieve ﬂow rates between 25 and
35 L min1, see Fig. 9b. Patient 2 represents a generic patient with
Fig. 9. Illustrative inhalation proﬁles: (a) Patient 1, with normal lung function; (b) Patient 2, with reduced lung function. The corresponding drug release proﬁles for different
bypass-to-entrainment-ﬂow ratios r: (c) Patient 1 with optimized r = 6.7; (d) Patient 2 with optimized r = 1.9; (e) Patient 1 with r = 4.3; (f) Patient 2 with r = 4.3.
T. Kopsch et al. / International Journal of Pharmaceutics 529 (2017) 589–596 595reduced lung function, for example in elderly patients or in those
with severe COPD (Al-showair et al., 2007; Broeders et al., 2001).
The optimization algorithm was used to adjust r, the ratio of bypass
to entrainment ﬂow, for each patient to best achieve the desired
target release behaviour. For patient 1 the optimized ratio was
found to be r = 6.7; for patient 2 the optimized ratio was found to be
r = 1.9. Fig. 9c and d show the release proﬁles with the optimized
bypass for patient 1 and 2 respectively. For comparison, Fig. 9e and
f show the release proﬁles when the same, non-optimized, ratio
r = 4.3 is chosen for both patients (a ‘one size ﬁts all’ approach). For
this choice of r good agreement with the target proﬁle Mtarget
could not be achieved: for patient 1 (high lung function) drug
powder is released too early, for patient 2 (low lung function) drug
powder is released too late.4. Discussion & conclusions
In summary, an optimization method has been developed to
identify the optimal amount of bypass needed in a DPI for a
particular patient. This method relies on a computational meta-
model that can predict drug release from a device accurately.
Compared to a high-ﬁdelity CFD modelling approach the meta-
model approach presented in this study can obtain results up to a
million times faster. Consequently, it can easily be used as part of a
bypass optimization process in which a large number of
predictions have to be made.
The effectiveness of the optimization method has been shown
by means of a numerical study. By identifying the optimal amount
of bypass for particular patients a close match between drug
596 T. Kopsch et al. / International Journal of Pharmaceutics 529 (2017) 589–596release proﬁles and a desired target release proﬁle was obtained.
This optimization method may be applied to develop a DPI with a
settable amount of bypass.
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